<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Evid Based Complement Alternat Med</journal-id><journal-id journal-id-type="iso-abbrev">Evid Based Complement Alternat Med</journal-id><journal-id journal-id-type="publisher-id">ECAM</journal-id><journal-title-group><journal-title>Evidence-based Complementary and Alternative Medicine : eCAM</journal-title></journal-title-group><issn pub-type="ppub">1741-427X</issn><issn pub-type="epub">1741-4288</issn><publisher><publisher-name>Hindawi</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29317896</article-id><article-id pub-id-type="pmc">5727636</article-id><article-id pub-id-type="doi">10.1155/2017/7901670</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Effect of Peony-Glycyrrhiza Decoction on Amisulpride-Induced Hyperprolactinemia in Women with Schizophrenia: A Preliminary Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Ping</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Liang</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Dong</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Chaoying</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Peng</surname><given-names>Hongli</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-7803-3425</contrib-id><name><surname>Huang</surname><given-names>Huiyong</given-names></name><email>huanghy68@126.com</email><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3676-9930</contrib-id><name><surname>Liu</surname><given-names>Xuejun</given-names></name><email>707151907@qq.com</email><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>Department of Psychiatry, Brains Hospital of Hunan Province, Changsha, China</aff><aff id="I2">
<sup>2</sup>Provincial Key Laboratory of TCM Diagnostics, Hunan University of Chinese Medicine, Changsha, China</aff><author-notes><fn fn-type="other"><p>Academic Editor: Nunziatina De Tommasi</p></fn></author-notes><pub-date pub-type="ppub"><year>2017</year></pub-date><pub-date pub-type="epub"><day>26</day><month>11</month><year>2017</year></pub-date><volume>2017</volume><elocation-id>7901670</elocation-id><history><date date-type="received"><day>4</day><month>6</month><year>2017</year></date><date date-type="accepted"><day>12</day><month>10</month><year>2017</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2017 Ping Yang et al.</copyright-statement><copyright-year>2017</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p> The aim of this study is to observe the effect of Peony-Glycyrrhiza Decoction (PGD) on hyperprolactinemia in women with schizophrenia induced by Amisulpride.</p></sec><sec><title> Material and Methods</title><p> A total of 41 female schizophrenia patients receiving Amisulpride were randomly divided into placebo (<italic>n</italic> = 20) and PGD groups (<italic>n</italic> = 21). Maintaining the original Amisulpride dose, the two groups were given placebo and PGD, respectively. The levels of Prolactin (PRL) and other hormones were measured on the initial day and at weeks 4 and 8 after treatment. Changes of clinical symptoms in patients with hyperprolactinemia were observed. The PANSS scores were recorded to assess the psychotic symptoms.</p></sec><sec><title> Results</title><p> Compared with placebo group, level of PRL decreased while Progesterone increased remarkably in the PGD group at weeks 4 and 8 (<italic>p</italic> &#x0003c; 0.01), and level of Estradiol in the PGD group increased significantly at week 8 (<italic>p</italic> &#x0003c; 0.05). There were no differences in PANSS scores and biochemical indexes between two groups at weeks 4 and 8.</p></sec><sec><title> Conclusion</title><p> PGD can improve symptoms of hyperprolactinemia and hormone levels in women with schizophrenia caused by Amisulpride, without affecting their mental symptoms and biochemical indexes.</p></sec></abstract><funding-group><award-group><funding-source>National Natural Science Foundation of China</funding-source><award-id>81302899</award-id><award-id>81373551</award-id><award-id>81603512</award-id></award-group><award-group><funding-source>Hunan Provincial Science and Technology Department</funding-source><award-id>2014TT2013</award-id></award-group><award-group><funding-source>Institute of Chinese Materia Medica</funding-source></award-group></funding-group></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Schizophrenia, a severe mental illness, with high prevalence rate and disability rate, has been characterized by hallucinations, delusional perception, delusions of control, thought disorders, and social function withdrawal [<xref rid="B1" ref-type="bibr">1</xref>]. The use of antipsychotic medications is still the main therapeutic method, which can stabilize the patient's mental symptoms, even help them recover social function and return to society [<xref rid="B2" ref-type="bibr">2</xref>]. However, the long-term use of antipsychotic medications may lead to a large quantity of adverse reactions, such as the extrapyramidal reaction in the nervous system, leucopenia in the blood system, and Prolactin (PRL) and metabolic disorders in the endocrine system. It will affect the patient's physical health, treatment compliance, and therapeutic effect greatly [<xref rid="B3" ref-type="bibr">3</xref>]. If the adverse reactions could not be controlled in time, the patient may have to face the dilemma of drug withdrawal, which subsequently results in disease recurrence [<xref rid="B4" ref-type="bibr">4</xref>].</p><p>The majority of antipsychotic medications in clinic, such as Haloperidol, Chlorpromazine, Risperidone, Amisulpride, Sulpiride, and Olanzapine, will bring hyperprolactinemia [<xref rid="B5" ref-type="bibr">5</xref>]. Some study showed that the prevalence of hyperprolactinemia induced by antipsychotic medications was 42%&#x02013;89% in schizophrenia patients [<xref rid="B6" ref-type="bibr">6</xref>]. In recent years, with the use of Risperidone and Amisulpride, two atypical antipsychotics, the prevalence was as high as 70%&#x02013;100% [<xref rid="B7" ref-type="bibr">7</xref>], and it was even higher in young patients, especially young women [<xref rid="B8" ref-type="bibr">8</xref>]. The hyperprolactinemia has been regarded as the most common adverse reaction.</p><p>PRL is a polypeptide hormone, synthesized and secreted by luteotroph in the anterior pituitary, and its main function is to regulate reproduction, lactation, and puerpera behavior [<xref rid="B9" ref-type="bibr">9</xref>]. Hyperprolactinemia refers to a kind of pathologic status, in which the level of peripheral serum PRL increases continuously [<xref rid="B10" ref-type="bibr">10</xref>]. Antipsychotic medications may block the anterior pituitary D2 receptor directly, subsequently weaken the inhibition effect of the dopamine on the secretion of luteotroph, and then cause the ascending of PRL [<xref rid="B11" ref-type="bibr">11</xref>]. Nearly all the typical antipsychotics had a strong affinity for D2 receptors. Once they are combined with D2 receptor, the dissociation rate is much too slow, which lead to persistent ascending of PRL. However, atypical antipsychotics have different dissociation rates with D2 receptors, so they differed on the effect of the PRL secretion [<xref rid="B12" ref-type="bibr">12</xref>]. Both the parent drug and active metabolite of Risperidone or Amisulpride have a strong effect on peripheral and central dopamine receptors, resulting in hyperprolactinemia [<xref rid="B13" ref-type="bibr">13</xref>].</p><p>Hyperprolactinemia may cause short-term menstrual disorders, distending pain of the breast, lactation, and sexual dysfunction. If it lasts for a long time, the effect to reproductive development, bone density, and cardiovascular system will come into being [<xref rid="B14" ref-type="bibr">14</xref>]. Therefore, the treatment to hyperprolactinemia is of great importance. At present, the first-use drug is Bromocriptine [<xref rid="B15" ref-type="bibr">15</xref>], but it will bring depravation of psychiatric symptoms, tremor, and other side effects easily in women with schizophrenia. Risks are more higher than benefits [<xref rid="B16" ref-type="bibr">16</xref>]. Studies have also shown that Aripiprazole can significantly reduce the level of PRL induced by Risperidone [<xref rid="B17" ref-type="bibr">17</xref>]. However, the combined use of two or more antipsychotic drugs will lead to higher incidence of adverse reaction.</p><p>In recent years, the intervention of Chinese herbs in hyperprolactinemia caused by antipsychotic drugs has been studied. The results showed that Peony-Glycyrrhiza Decoction (PGD) could increase the binding capacity of dopamine receptor, inhibit the secretion of PRL [<xref rid="B18" ref-type="bibr">18</xref>], and significantly reduce the level of Risperidone-induced PRL [<xref rid="B19" ref-type="bibr">19</xref>]. Therefore, in this study, we aimed to observe the clinical effect of PGD on Amisulpride-induced hyperprolactinemia in female schizophrenia patient, then detect the changes of levels of PRL and other related hormones, and assess whether it is safe and reliable or not. The results will not only provide the clinical basis for further study on the mechanism of PGD treating Amisulpride-induced hyperprolactinemia, but also widen the eyesight for the prevention and treatment research of Chinese herbs to the antipsychotics-induced adverse reactions.</p></sec><sec id="sec2"><title>2. Materials and Methods</title><sec id="sec2.1"><title>2.1. Participants and Study Design</title><p>In this study, female participants aged 18&#x02013;40 years with diagnosis of paranoid schizophrenia (F20.0 according to ICD-10 (10th revision of the International Statistical Classification of Diseases and Related Health Problems)) were screened. Majority of return visits were conducted in outpatient clinics; only few were finished in inpatient department. Patients in stable physical, neurological, and endocrinological condition with normal laboratory values (blood tests and biochemical tests, including liver, kidney, and thyroid parameters) were enrolled to the study. Clinical inclusion criteria included (1) taking Amisulpride monotherapy for at least 3 months; (2) stable mental state, stable treatment for at least 3 months, and PANSS scores less than 60 [<xref rid="B20" ref-type="bibr">20</xref>]; (3) level of serum PRL higher than 24&#x02009;ng/mL [<xref rid="B21" ref-type="bibr">21</xref>]; (4) at least one overt hyperprolactinemia-related symptom, including amenorrhea, abnormal menstruation, galactorrhea, reduced libido, or sexlessness; (5) screening negative for pregnancy in women and agreeing to use effective contraception methods during the study. The protocol of this study was approved by the medical ethical committee of Brains Hospital of Hunan Province. All participants and their guardians were given the voluntary, written, and informed consent before entering the trial. Patients who had any of the following conditions were excluded from the study: (1) PRL pituitary adenoma, polycystic ovary syndrome, and other serious somatic diseases; (2) a history of neuroleptic malignant syndrome or tardive dyskinesia; (3) suicide ideas or attempts or aggressive behavior; (4) a history of alcoholism and drug abuse in the past 1 year; (5) currently treated with other endocrine drugs, Chinese medicine, and other natural products; (6) a history of allergy to herbal medicine; and (7) lactating.</p><p>This is a preliminary study. The double-blind, randomized, placebo-controlled trial, lasting for 2 months, was conducted between January 2014 and February 2017 in the Department of Psychiatry of Brains Hospital of Hunan Province. A total of 41 patients were included in this study. Patients were randomly divided into placebo (<italic>n</italic> = 20) and PGD groups (<italic>n</italic> = 21). The baseline characteristics of patients were tested before this study.</p></sec><sec id="sec2.2"><title>2.2. Products</title><p>Placebo was provided by Jiuzhitang Co., Ltd., which was made of auxiliary materials, containing no medicine. The appearance and dosage form had no difference from PGD.</p><p>PGD was also entrusted to Jiuzhitang Co., Ltd. The standardized preparation of PGD was established in Jiuzhitang Co., Ltd., in compliance with Pharmacopoeia of China [<xref rid="B22" ref-type="bibr">22</xref>] and Good Manufacture Practice of Medical Products. Briefly, sliced and broiled Paeoniae Radix Alba (60&#x02009;mg) and Glycyrrhiza Radix Et Rhizoma (30&#x02009;mg) in a ratio of 2&#x02009;:&#x02009;1 in weight were immersed and boiled in an 8-fold volume of distilled water for 2.5 hours. The placebo and intervention were identical in appearance, taste, and smell. The contents of three major known pharmacologically active constituents of PGD (paeoniflorin, liquiritin, and glycyrrhizic acid) were measured using Ultra Performance Liquid Chromatography (UPLC) and the result was shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>. The UPLC profile of the PGD preparation used in this study was highly comparable with those used in previous studies.</p></sec><sec id="sec2.3"><title>2.3. Treatments</title><p>Participants were randomly allocated to receive either PGD or a placebo twice a day for 8 weeks. They were asked not to alter their antipsychotic medication during the intervention period. This was monitored at monthly visits. A double-blind follow-up visit was conducted 8 weeks after the completion of the treatment. Participants were required to attend biweekly or monthly visits during the study.</p><p>During the course of the study, patients were allowed to have concomitant treatment with other psychotropic drugs. These mainly included agents for the treatment of extrapyramidal symptoms and insomnia, for example, Benzhexol Hydrochloride and Benzodiazepines. Adjustment of dosage and addition and termination of psychotropic medication were conducted at the discretion of the participant's psychiatrist, on the basis of the individual. Concomitant use of other herbal and natural products was not allowed during the study period.</p></sec><sec id="sec2.4"><title>2.4. Measurements</title><p>All measurements were taken three times at the beginning of this study, weeks 4 and 8 after treatment. Three 10&#x02009;mL blood samples for hormones assay were obtained. Each sample was collected from the cubital fossa veins between 8:00 and 9:00 a.m. before meal and centrifuged at 1000&#x02009;G for 10 minutes at 4&#x000b0;C. Sera were then separated and stored at &#x02212;20&#x000b0;C for assay. Serum concentrations of PRL, Estradiol, Progesterone, FSH, and LH were measured using chemiluminescent immunoassay.</p><p>In order to ensure the safety of medication, all patients liver and kidney function, blood glucose, blood lipid, and TSH in the initial day and at week 8 were detected. The TESS was evaluated independently by 2 elder attending physicians, and the concordance correlation coefficient &#x0003e; 0.88.</p></sec><sec id="sec2.5"><title>2.5. Clinical Assessments</title><p>Clinical symptoms of schizophrenia were assessed using PANSS scores and its subscores (positive, negative, and general symptoms) [<xref rid="B20" ref-type="bibr">20</xref>] in the initial day and at weeks 4 and 8 after treatment. Record the changes in symptoms, such as amenorrhea, abnormal menstruation, galactorrhea, reduced libido, and sexlessness.</p></sec><sec id="sec2.6"><title>2.6. Statistical Analysis</title><p>The randomization code was not broken until all data were collected. Statistical analysis was performed using SPSS 24.0. For continuous variables, descriptive statistics (means, standard deviations, and 95% confidence interval) were calculated, while for discrete variables number of patients and percentages are given. Shapiro-Wilk test was used to test normality of distribution, and variables that did not follow normal distribution were transformed for best normality. Means, standard deviations, and confidence intervals are reported for nontransformed variables, and results of tests are reported for transformed or nontransformed variables. The difference between proportions was analyzed by Fisher's exact test, while intergroup differences were assessed by <italic>t</italic>-test. <italic>p</italic> values less than 0.05 were considered as significant and those less than 0.01 were significant remarkably.</p></sec></sec><sec id="sec3"><title>3. Results</title><sec id="sec3.1"><title>3.1. Baseline Characteristics of Patients</title><p>The two groups of patients were given placebo and PGD, respectively, lasting for 8 weeks. In the end, 34 of them have completed this study. In the placebo group, 5 patients were lost (25%), among them 2 patients had to quit because of severe akathisia and 3 patients due to amenorrhea after 4 weeks, while in the PGD group only 2 patients were lost (9.52%) for extrapyramidal side effect after 4 weeks. It was a double-blind study. The baseline characteristics of patients are shown in <xref ref-type="table" rid="tab1">Table 1</xref>. No significant differences on baseline variables were observed between these 2 groups.</p></sec><sec id="sec3.2"><title>3.2. Levels of PRL and Other Hormones</title><p>Figures <xref ref-type="fig" rid="fig2">2</xref><xref ref-type="fig" rid="fig3"/><xref ref-type="fig" rid="fig4"/><xref ref-type="fig" rid="fig5"/>&#x02013;<xref ref-type="fig" rid="fig6">6</xref> represent levels of PRL, Estradiol, Progesterone, Follicle-stimulating hormone (FSH), and Luteinizing hormone (LH) at three different time points (initial, weeks 4 and 8). There were no differences in all hormones between these 2 groups at the beginning of the study. Levels of PRL have statistical significance at week 4 (placebo: 45.75 &#x000b1; 5.57&#x02009;ng/mL, PGD: 26.74 &#x000b1; 4.03&#x02009;ng/mL, <italic>p</italic> = 0.00) and week 8 (placebo: 45.27 &#x000b1; 4.53&#x02009;ng/mL, PGD: 25.00 &#x000b1; 4.31&#x02009;ng/mL, <italic>p</italic> = 0.00). Levels of Estradiol have no statistical significance at week 4 (placebo: 56.31 &#x000b1; 25.95&#x02009;pg/mL, PGD: 71.68 &#x000b1; 20.61&#x02009;pg/mL, <italic>p</italic> = 0.06) but have statistical significance at week 8 (placebo: 52.73 &#x000b1; 24.65&#x02009;pg/mL, PGD: 70.89 &#x000b1; 17.53&#x02009;pg/mL, <italic>p</italic> = 0.02). Levels of Progesterone have statistical significance at week 4 (placebo: 14.63 &#x000b1; 2.68&#x02009;ng/mL, PGD: 29.00 &#x000b1; 4.29&#x02009;ng/mL, <italic>p</italic> = 0.00) and week 8 (placebo: 15.13 &#x000b1; 3.02&#x02009;ng/mL, PGD: 30.58 &#x000b1; 3.15&#x02009;ng/mL, <italic>p</italic> = 0.00). Levels of FSH have no statistical significance at week 4 (placebo: 14.88 &#x000b1; 3.22&#x02009;IU/L, PGD: 14.63 &#x000b1; 2.36&#x02009;IU/L, <italic>p</italic> = 0.80) and week 8 (placebo: 14.20 &#x000b1; 1.52&#x02009;IU/L, PGD: 15.68 &#x000b1; 2.71&#x02009;IU/L, <italic>p</italic> = 0.07). Levels of LH have no statistical significance at week 4 (placebo: 27.25 &#x000b1; 10.03&#x02009;IU/L, PGD: 21.95 &#x000b1; 6.13&#x02009;IU/L, <italic>p</italic> = 0.08) and week 8 (placebo: 28.07 &#x000b1; 8.19&#x02009;IU/L, PGD: 23.37 &#x000b1; 5.08&#x02009;IU/L, <italic>p</italic> = 0.06).</p></sec><sec id="sec3.3"><title>3.3. Biochemical Indexes</title><p>The biochemical indexes of patients at week 8 in the study are shown in <xref ref-type="table" rid="tab2">Table 2</xref>. There are no significant differences in hepatorenal function, blood glucose, blood lipid, and TSH between the two groups.</p></sec><sec id="sec3.4"><title>3.4. Treatment Emergent Symptom Scale (TESS)</title><p>After 8 weeks' treatment, the incidence of adverse reactions in TESS (NIMH, 1973) was 3/15 in the placebo group and 5/19 in the PGD group, respectively. The difference between these two groups has no statistical significance (<italic>X</italic><sub>2</sub> = 1.11, <italic>p</italic> &#x0003e; 0.05).</p></sec><sec id="sec3.5"><title>3.5. Positive and Negative Syndrome Scale (PANSS) Scores and Improvement of Hyperprolactinemia-Related Symptoms</title><p>PANSS scores (<xref ref-type="fig" rid="fig7">Figure 7</xref>) have no statistical significance at the beginning of the study (placebo: 50.45 &#x000b1; 4.05, PGD: 52.76 &#x000b1; 4.65, <italic>p</italic> = 0.10), week 4 (placebo: 51.31 &#x000b1; 5.29, PGD: 49.58 &#x000b1; 5.93, <italic>p</italic> = 0.40), and week 8 (placebo: 52.73 &#x000b1; 3.45, PGD: 50.95 &#x000b1; 5.98, <italic>p</italic> = 0.85). At week 8, there was no improvement of hyperprolactinemia-related symptoms in the placebo group. On the contrary, 15 patients in the PGD group improved hyperprolactinemia-related symptoms in different aspects, among them, 2 cases in amenorrhea, 4 cases in abnormal menstruation, 3 cases in galactorrhea, 4 cases in reduced libido, and 2 cases in sexlessness.</p></sec></sec><sec id="sec4"><title>4. Discussion</title><p>A great number of studies have shown that western medicine, such as Bromocriptine, Aripiprazole, and other drugs, will do antipsychotic-induced hyperprolactinemia more harm than good [<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B24" ref-type="bibr">24</xref>]. Side effects of drugs are the most important factors leading to the withdrawal of medicine [<xref rid="B25" ref-type="bibr">25</xref>]. Therefore, the urgent priority is how to alleviate the side effects of antipsychotic drugs. Previous studies in cultured cells and animals suggested that PGD, a famous traditional Chinese decoction, would be effective in reducing the symptoms of antipsychotics-related hyperprolactinemia [<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B27" ref-type="bibr">27</xref>]. At present, clinical trials have successfully proved that the PGD can significantly reduce the symptoms of hyperprolactinemia caused by antipsychotic drugs [<xref rid="B19" ref-type="bibr">19</xref>]. However, the majority of the studies focused on the hyperprolactinemia induced by Risperidone, Sulpiride, and Olanzapine [<xref rid="B28" ref-type="bibr">28</xref>&#x02013;<xref rid="B30" ref-type="bibr">30</xref>]; the data describing the Amisulpride-induced hyperprolactinemia were rare, which may be associated with its infrequent use in clinic. Meanwhile, the domestic investigation showed that Aripiprazole is effective in high PRL caused by Risperidone, but ineffective in that induced by Amisulpride [<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B32" ref-type="bibr">32</xref>]. With the increase of schizophrenia patients treated with Amisulpride in our hospital in recent years, evidences have stated that Amisulpride-induced hyperprolactinemia has risen, especially in female patients. This status will result in many problems, such as reproductive development and bone density abnormality, which lead to the decline of compliance and disease recurrence. Hence, we selected some eligible patients to participate in this study.</p><p>The PGD contained the following: 60&#x02009;g Paeoniae Radix Alba and 30&#x02009;g Glycyrrhiza Radix Et Rhizoma. According to previous studies on the treatment of Qi-deficiency and blood-stasis syndrome, the ratio of Paeoniae Radix Alba to Glycyrrhiza Radix Et Rhizoma in PGD should be 1&#x02009;:&#x02009;1 [<xref rid="B33" ref-type="bibr">33</xref>]. However, in the treatment of hyperprolactinemia, a large number of studies have suggested that the ratio of 2&#x02009;:&#x02009;1 may be better [<xref rid="B34" ref-type="bibr">34</xref>]. Therefore, we choose this medicine compatibility in our experiment. As a result, we found that the levels of PRL and Progesterone were significantly improved with the treatment of PGD after 4 weeks, and the levels of PRL, Estradiol, and Progesterone were significantly improved after 8 weeks. Hyperprolactinemia-related symptoms of 15 patients in different aspects have been improved. It suggested that the level of PRL may be related to the regulation of hormones, and the PGD may inhibit the secretion of PRL by regulating the hormones level [<xref rid="B26" ref-type="bibr">26</xref>]. However, some scholars said that although the PGD can improve the symptoms of hyperprolactinemia caused by antipsychotics, the level of PRL did not change significantly [<xref rid="B19" ref-type="bibr">19</xref>]. The possible reason may be related to normalization of sex hormone dysfunction via dopaminergic action upon the hypothalamic-pituitary-gonadal axis [<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B36" ref-type="bibr">36</xref>]. So, such a result we got may be associated with the medicine of Amisulpride we chose. Amisulpride has a strong affinity for D2 receptors, and their dissociation rate is much too slow [<xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B38" ref-type="bibr">38</xref>]. Amisulpride has a high selectivity to the central nervous system, affecting the mesolimbic system. While the rate of Amisulpride passing through the blood brain barrier is too low, the possessing rate to hypophyseal dopamine receptor is significantly higher than that to the middle part of the limbic system [<xref rid="B39" ref-type="bibr">39</xref>], which increases the impact to serum PRL in patients. This may be the difference between Amisulpride and other antipsychotic medications. Of course, our conclusion should be confirmed by further studies because we have not verified that PGD can change the level of PRL by regulating D2 receptor.</p><p>Considering that the high dose of PGD may increase the side effects to patients, our study detected the liver and kidney function, blood lipids, blood glucose, and thyroid hormone, combined with the TESS to assess the safety of the medication. Fortunately, the parameters above did not change too much after 8 weeks' treatment in PGD group, and the TESS did not show overt side effects. Although some extrapyramidal reactions appeared, they were controlled easily by using trihexyphenidyl hydrochloride. The improvement of corresponding symptoms by traditional Chinese medicine has given the patients confidence to finish this study, resulting in such low expulsion rate.</p><p>From all above, when western medicine cannot relieve Amisulpride-induced hyperprolactinemia, the PGD may work. This traditional Chinese decoction is simple and effective, with low side effect, which is worth being popularized in clinic. Further studies should be carried out to investigate the mechanism of how does it affect hyperprolactinemia.</p></sec></body><back><ack><title>Acknowledgments</title><p>This work was supported by grants from the National Natural Science Foundation of China (nos. 81302899, 81373551, and 81603512) and Science and Research Program of Hunan Department of Science and Technology (no. 2014TT2013). The authors are grateful for the support provided by the Institute of Chinese Materia Medica, Hunan Academy of Traditional Chinese Medicine, Changsha, Hunan Province, China.</p></ack><glossary><title>Abbreviations</title><def-list><def-item><term>PGD:</term><def><p>Peony-Glycyrrhiza Decoction</p></def></def-item><def-item><term>PRL:</term><def><p>Prolactin</p></def></def-item><def-item><term>UPLC:</term><def><p>Ultra Performance Liquid Chromatography</p></def></def-item><def-item><term>PANSS:</term><def><p>Positive and Negative Syndrome Scale</p></def></def-item><def-item><term>CI:</term><def><p>Confidential intervals</p></def></def-item><def-item><term>TESS:</term><def><p>Treatment Emergent Symptom Scale.</p></def></def-item></def-list></glossary><sec><title>Conflicts of Interest</title><p>The authors declare that there are no conflicts of interest regarding the publication of this article.</p></sec><sec><title>Authors' Contributions</title><p>Ping Yang and Liang Li contributed equally.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polimanti</surname><given-names>R.</given-names></name><name><surname>Agrawal</surname><given-names>A.</given-names></name><name><surname>Gelernter</surname><given-names>J.</given-names></name></person-group><article-title>Schizophrenia and substance use comorbidity: A genome-wide perspective</article-title><source><italic>Genome Medicine</italic></source><year>2017</year><volume>9</volume><issue>1, article no. 25</issue><pub-id pub-id-type="other">2-s2.0-85015964636</pub-id><pub-id pub-id-type="doi">10.1186/s13073-017-0423-3</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McEvoy</surname><given-names>J. P.</given-names></name><name><surname>Byerly</surname><given-names>M.</given-names></name><name><surname>Hamer</surname><given-names>R. M.</given-names></name><etal/></person-group><article-title>Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial</article-title><source><italic>Journal of the American Medical Association</italic></source><year>2014</year><volume>311</volume><issue>19</issue><fpage>1978</fpage><lpage>1986</lpage><pub-id pub-id-type="doi">10.1001/jama.2014.4310</pub-id><pub-id pub-id-type="other">2-s2.0-84900820152</pub-id><pub-id pub-id-type="pmid">24846035</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masilamoni</surname><given-names>G. J.</given-names></name><name><surname>Uthayathas</surname><given-names>S.</given-names></name><name><surname>Koenig</surname><given-names>G.</given-names></name><name><surname>Leventhal</surname><given-names>L.</given-names></name><name><surname>Papa</surname><given-names>S. M.</given-names></name></person-group><article-title>Effects of a novel phosphodiesterase 10A inhibitor in non-human primates: A therapeutic approach for schizophrenia with improved side effect profile</article-title><source><italic>Neuropharmacology</italic></source><year>2016</year><volume>110</volume><fpage>449</fpage><lpage>457</lpage><pub-id pub-id-type="other">2-s2.0-84983315100</pub-id><pub-id pub-id-type="doi">10.1016/j.neuropharm.2016.08.012</pub-id><pub-id pub-id-type="pmid">27539962</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keith</surname><given-names>S. J.</given-names></name><name><surname>Kane</surname><given-names>J. M.</given-names></name></person-group><article-title>Partial compliance and patient consequences in schizophrenia: our patients can do better</article-title><source><italic>Journal of Clinical Psychiatry</italic></source><year>2003</year><volume>64</volume><issue>11</issue><fpage>1308</fpage><lpage>1315</lpage><pub-id pub-id-type="doi">10.4088/JCP.v64n1105</pub-id><pub-id pub-id-type="other">2-s2.0-0344119580</pub-id><pub-id pub-id-type="pmid">14658944</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bo</surname><given-names>Q.-J.</given-names></name><name><surname>Wang</surname><given-names>Z.-M.</given-names></name><name><surname>Li</surname><given-names>X.-B.</given-names></name><name><surname>Ma</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>C.-Y.</given-names></name><name><surname>de Leon</surname><given-names>J.</given-names></name></person-group><article-title>Adjunctive metformin for antipsychotic-induced hyperprolactinemia: a systematic review</article-title><source><italic>Psychiatry Research</italic></source><year>2016</year><volume>237</volume><fpage>257</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1016/j.psychres.2016.01.031</pub-id><pub-id pub-id-type="other">2-s2.0-84959175714</pub-id><pub-id pub-id-type="pmid">26822064</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinon</surname><given-names>B. J.</given-names></name><name><surname>Gilmore</surname><given-names>J. A.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Halbreich</surname><given-names>U. M.</given-names></name></person-group><article-title>Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone</article-title><source><italic>Psychoneuroendocrinology</italic></source><year>2003</year><volume>28</volume><issue>2</issue><fpage>55</fpage><lpage>68</lpage><pub-id pub-id-type="other">2-s2.0-0037376682</pub-id><pub-id pub-id-type="doi">10.1016/S0306-4530(02)00127-0</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inder</surname><given-names>W. J.</given-names></name><name><surname>Castle</surname><given-names>D.</given-names></name></person-group><article-title>Antipsychotic-induced hyperprolactinaemia</article-title><source><italic>Australian &#x00026; New Zealand Journal of Psychiatry</italic></source><year>2011</year><volume>45</volume><issue>10</issue><fpage>830</fpage><lpage>837</lpage><pub-id pub-id-type="other">2-s2.0-80053993106</pub-id><pub-id pub-id-type="doi">10.3109/00048674.2011.589044</pub-id><pub-id pub-id-type="pmid">21714721</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubio-Abadal</surname><given-names>E.</given-names></name><name><surname>Del Cacho</surname><given-names>N.</given-names></name><name><surname>Saenz-Navarrete</surname><given-names>G.</given-names></name><etal/></person-group><article-title>How hyperprolactinemia affects sexual function in patients under antipsychotic treatment</article-title><source><italic>Journal of Clinical Psychopharmacology</italic></source><year>2016</year><volume>36</volume><issue>5</issue><fpage>422</fpage><lpage>428</lpage><pub-id pub-id-type="other">2-s2.0-84978698000</pub-id><pub-id pub-id-type="doi">10.1097/JCP.0000000000000539</pub-id><pub-id pub-id-type="pmid">27433851</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanasaki</surname><given-names>H.</given-names></name><name><surname>Oride</surname><given-names>A.</given-names></name><name><surname>Hara</surname><given-names>T.</given-names></name><name><surname>Mijiddorj</surname><given-names>T.</given-names></name><name><surname>Sukhbaatar</surname><given-names>U.</given-names></name><name><surname>Kyo</surname><given-names>S.</given-names></name></person-group><article-title>Interactions between two different G protein-coupled receptors in reproductive hormone-producing cells: the role of PACAP and its receptor PAC1R</article-title><source><italic>International Journal of Molecular Sciences</italic></source><year>2016</year><volume>17</volume><issue>10, article no. 1635</issue><pub-id pub-id-type="doi">10.3390/ijms17101635</pub-id><pub-id pub-id-type="other">2-s2.0-84989360953</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montejo</surname><given-names>&#x000c1;. L.</given-names></name><name><surname>Arango</surname><given-names>C.</given-names></name><name><surname>Bernardo</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics</article-title><source><italic>Frontiers in Neuroendocrinology</italic></source><year>2017</year><volume>45</volume><fpage>25</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.yfrne.2017.02.003</pub-id><pub-id pub-id-type="other">2-s2.0-85014205182</pub-id><pub-id pub-id-type="pmid">28235557</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwata</surname><given-names>Y.</given-names></name><name><surname>Nakajima</surname><given-names>S.</given-names></name><name><surname>Caravaggio</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Threshold of dopamine D2/3 receptor occupancy for hyperprolactinemia in older patients with schizophrenia</article-title><source><italic>Journal of Clinical Psychiatry</italic></source><year>2016</year><volume>77</volume><issue>12</issue><fpage>e1557</fpage><lpage>e1563</lpage><pub-id pub-id-type="other">2-s2.0-85007608229</pub-id><pub-id pub-id-type="doi">10.4088/JCP.15m10538</pub-id><pub-id pub-id-type="pmid">28086010</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lertxundi</surname><given-names>U.</given-names></name><name><surname>Domingo-Echaburu</surname><given-names>S.</given-names></name><name><surname>Peral</surname><given-names>J.</given-names></name><name><surname>Garcia</surname><given-names>M.</given-names></name></person-group><article-title>Antipsychotic induced symptomatic hyperprolactinemia: are dopamine agonists safe?</article-title><source><italic>Psychopharmacol Bull</italic></source><year>2011</year><volume>44</volume><issue>3</issue><fpage>66</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">27738363</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fric</surname><given-names>M.</given-names></name><name><surname>Laux</surname><given-names>G.</given-names></name></person-group><article-title>Prolactin levels and symptoms of hyperprolactinemia in patients treated with amisulpride, risperidone, olanzapine and quetiapine</article-title><source><italic>Psychiatrische Praxis, Supplement</italic></source><year>2003</year><volume>30</volume><issue>2</issue><fpage>S97</fpage><lpage>S101</lpage><pub-id pub-id-type="other">2-s2.0-0038451516</pub-id><pub-id pub-id-type="doi">10.1055/s-2003-39764</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romijn</surname><given-names>J. A.</given-names></name></person-group><article-title>Hyperprolactinemia and prolactinoma</article-title><source><italic>Handbook of Clinical Neurology</italic></source><year>2014</year><volume>124</volume><fpage>185</fpage><lpage>195</lpage><pub-id pub-id-type="other">2-s2.0-84907541199</pub-id><pub-id pub-id-type="doi">10.1016/B978-0-444-59602-4.00013-7</pub-id><pub-id pub-id-type="pmid">25248588</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arduc</surname><given-names>A.</given-names></name><name><surname>Gokay</surname><given-names>F.</given-names></name><name><surname>Isik</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Retrospective comparison of cabergoline and bromocriptine effects in hyperprolactinemia: a single center experience</article-title><source><italic>Journal of Endocrinological Investigation</italic></source><year>2015</year><volume>38</volume><issue>4</issue><fpage>447</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1007/s40618-014-0212-4</pub-id><pub-id pub-id-type="other">2-s2.0-84941781798</pub-id><pub-id pub-id-type="pmid">25421155</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>H.-N.</given-names></name><name><surname>Wang</surname><given-names>C.-Y.</given-names></name><name><surname>Sze</surname><given-names>C. W.</given-names></name><etal/></person-group><article-title>A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with Schizophrenia</article-title><source><italic>Journal of Clinical Psychopharmacology</italic></source><year>2008</year><volume>28</volume><issue>3</issue><fpage>264</fpage><lpage>270</lpage><pub-id pub-id-type="other">2-s2.0-51449084310</pub-id><pub-id pub-id-type="doi">10.1097/JCP.0b013e318172473c</pub-id><pub-id pub-id-type="pmid">18480682</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>H. W.</given-names></name><name><surname>Lee</surname><given-names>J. S.</given-names></name><name><surname>Park</surname><given-names>S. J.</given-names></name><etal/></person-group><article-title>Comparing the effectiveness and safety of the addition of and switching to aripiprazole for resolving antipsychotic-induced hyperprolactinemia: A multicenter, open-label, prospective study</article-title><source><italic>Clinical Neuropharmacology</italic></source><year>2016</year><volume>39</volume><issue>6</issue><fpage>288</fpage><lpage>294</lpage><pub-id pub-id-type="other">2-s2.0-84979084851</pub-id><pub-id pub-id-type="doi">10.1097/WNF.0000000000000175</pub-id><pub-id pub-id-type="pmid">27438182</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Tian</surname><given-names>D.-D.</given-names></name><name><surname>Zheng</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Peony-glycyrrhiza decoction, an herbal preparation, inhibits clozapine metabolism via cytochrome p450s, but not flavin-containing monooxygenase in in vitro models</article-title><source><italic>Drug Metabolism and Disposition</italic></source><year>2015</year><volume>43</volume><issue>7</issue><fpage>1147</fpage><lpage>1153</lpage><pub-id pub-id-type="other">2-s2.0-84940372057</pub-id><pub-id pub-id-type="doi">10.1124/dmd.114.062653</pub-id><pub-id pub-id-type="pmid">25948710</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Man</surname><given-names>S. C.</given-names></name><name><surname>Li</surname><given-names>X.-B.</given-names></name><name><surname>Wang</surname><given-names>H.-H.</given-names></name><etal/></person-group><article-title>Peony-glycyrrhiza decoction for antipsychotic-related hyperprolactinemia in women with schizophrenia: a randomized controlled trial</article-title><source><italic>Journal of Clinical Psychopharmacology</italic></source><year>2016</year><volume>36</volume><issue>6</issue><fpage>572</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.1097/JCP.0000000000000607</pub-id><pub-id pub-id-type="other">2-s2.0-84991493070</pub-id><pub-id pub-id-type="pmid">27755159</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kay</surname><given-names>S. R.</given-names></name><name><surname>Fiszbein</surname><given-names>A.</given-names></name><name><surname>Opler</surname><given-names>L. A.</given-names></name></person-group><article-title>The positive and negative syndrome scale (PANSS) for schizophrenia</article-title><source><italic>Schizophrenia Bulletin</italic></source><year>1987</year><volume>13</volume><issue>2</issue><fpage>261</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1093/schbul/13.2.261</pub-id><pub-id pub-id-type="other">2-s2.0-0023606101</pub-id><pub-id pub-id-type="pmid">3616518</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biller</surname><given-names>B. M.</given-names></name><name><surname>Luciano</surname><given-names>A.</given-names></name><name><surname>Crosignani</surname><given-names>P. G.</given-names></name><etal/></person-group><article-title>Guidelines for the diagnosis and treatment of hyperprolactinemia</article-title><source><italic>Journal of Reproductive Medicine</italic></source><year>1999</year><volume>44</volume><issue>2</issue><fpage>1075</fpage><lpage>1084</lpage><pub-id pub-id-type="pmid">10649814</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>China Pharmacopoeia</surname><given-names>C.</given-names></name></person-group><source><italic>Pharmacopoeia of the People's Republic of China</italic></source><year>2010</year><volume>1</volume><edition>10th</edition><publisher-name>Chinese Medical Science and Technology Press</publisher-name></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bliesener</surname><given-names>N.</given-names></name><name><surname>Yokusoglu</surname><given-names>H.</given-names></name><name><surname>Quednow</surname><given-names>B. B.</given-names></name><name><surname>Klingm&#x000fc;ller</surname><given-names>D.</given-names></name><name><surname>K&#x000fc;hn</surname><given-names>K.-U.</given-names></name></person-group><article-title>Usefulness of bromocriptine in the treatment of amisulpride-induced hyperprolactinemia: a case report</article-title><source><italic>Pharmacopsychiatry</italic></source><year>2004</year><volume>37</volume><issue>4</issue><fpage>189</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1055/s-2004-827176</pub-id><pub-id pub-id-type="other">2-s2.0-3142684620</pub-id><pub-id pub-id-type="pmid">15467977</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voicu</surname><given-names>V.</given-names></name><name><surname>Medvedovici</surname><given-names>A.</given-names></name><name><surname>Ranetti</surname><given-names>A. E.</given-names></name><name><surname>R&#x001ce;dulescu</surname><given-names>F. &#x0015e;.</given-names></name></person-group><article-title>Drug-induced hypo- and hyperprolactinemia: mechanisms, clinical and therapeutic consequences</article-title><source><italic>Expert Opinion on Drug Metabolism &#x00026; Toxicology</italic></source><year>2013</year><volume>9</volume><issue>8</issue><fpage>955</fpage><lpage>968</lpage><pub-id pub-id-type="doi">10.1517/17425255.2013.791283</pub-id><pub-id pub-id-type="other">2-s2.0-84880383383</pub-id><pub-id pub-id-type="pmid">23600946</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Werner</surname><given-names>F.-M.</given-names></name><name><surname>Cove&#x000f1;as</surname><given-names>R.</given-names></name></person-group><article-title>Safety of antipsychotic drugs: focus on therapeutic and adverse effects</article-title><source><italic>Expert Opinion on Drug Safety</italic></source><year>2014</year><volume>13</volume><issue>8</issue><fpage>1031</fpage><lpage>1042</lpage><pub-id pub-id-type="doi">10.1517/14740338.2014.935761</pub-id><pub-id pub-id-type="other">2-s2.0-84904473696</pub-id><pub-id pub-id-type="pmid">24975932</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Wong</surname><given-names>H. K.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Not only dopamine D 2 receptors involved in peony-glycyrrhiza decoction, an herbal preparation against antipsychotic-associated hyperprolactinemia</article-title><source><italic>Progress in Neuro-Psychopharmacology &#x00026; Biological Psychiatry</italic></source><year>2012</year><volume>39</volume><issue>2</issue><fpage>332</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1016/j.pnpbp.2012.07.005</pub-id><pub-id pub-id-type="other">2-s2.0-84867024470</pub-id><pub-id pub-id-type="pmid">22796279</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Studies on the regulatory effect of peony-glycyrrhiza decoction on prolactin hyperactivity and underlying mechanism in hyperprolactinemia rat model</article-title><source><italic>Neuroscience Letters</italic></source><year>2015</year><volume>606</volume><fpage>60</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2015.08.024</pub-id><pub-id pub-id-type="other">2-s2.0-84940870584</pub-id><pub-id pub-id-type="pmid">26297122</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Huang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>The central mechanism of risperidone-induced hyperprolactinemia</article-title><source><italic>Progress in Neuro-Psychopharmacology &#x00026; Biological Psychiatry</italic></source><year>2017</year><volume>76</volume><fpage>134</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1016/j.pnpbp.2017.03.009</pub-id><pub-id pub-id-type="pmid">28336493</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cong</surname><given-names>Y.</given-names></name><name><surname>Zou</surname><given-names>H.</given-names></name><name><surname>Qiao</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Bilateral mammary duct ectasia induced by sulpiride-associated hyperprolactinemia: A case report</article-title><source><italic>Oncology Letters</italic></source><year>2015</year><volume>9</volume><issue>5</issue><fpage>2181</fpage><lpage>2184</lpage><pub-id pub-id-type="other">2-s2.0-84925398004</pub-id><pub-id pub-id-type="doi">10.3892/ol.2015.3034</pub-id><pub-id pub-id-type="pmid">26137036</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peuskens</surname><given-names>J.</given-names></name><name><surname>Pani</surname><given-names>L.</given-names></name><name><surname>Detraux</surname><given-names>J.</given-names></name><name><surname>de Hert</surname><given-names>M.</given-names></name></person-group><article-title>The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review</article-title><source><italic>CNS Drugs</italic></source><year>2014</year><volume>28</volume><issue>5</issue><fpage>421</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1007/s40263-014-0157-3</pub-id><pub-id pub-id-type="other">2-s2.0-84901481917</pub-id><pub-id pub-id-type="pmid">24677189</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>C. X.</given-names></name><name><surname>Huang</surname><given-names>W.</given-names></name><name><surname>Zhao</surname><given-names>X. H.</given-names></name><name><surname>Liang</surname><given-names>Z. T.</given-names></name><name><surname>Deng</surname><given-names>W.</given-names></name></person-group><article-title>Effect of various doses aripiprazole on hyperprolactinemia induced by amisulpride and risperidone</article-title><source><italic>Chinese Journal of Psychiatry</italic></source><year>2015</year><volume>48</volume><issue>5</issue><fpage>297</fpage><lpage>302</lpage></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J. N.</given-names></name><name><surname>Wang</surname><given-names>L. Y.</given-names></name><name><surname>Liu</surname><given-names>W. D.</given-names></name><name><surname>Du</surname><given-names>W. S.</given-names></name><name><surname>Liu</surname><given-names>W. B.</given-names></name></person-group><article-title>Efficacy of 2. 5,10,15&#x02009;mg aripiprazole in treating amisulpride and risperidone-induced hyperprolactinemia</article-title><source><italic>Chin J Biochem Pharm</italic></source><year>2016</year><volume>1</volume><fpage>114</fpage><lpage>115</lpage></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>L. Y.</given-names></name><name><surname>Yan</surname><given-names>S. Q.</given-names></name><name><surname>Wu</surname><given-names>S. Q.</given-names></name><name><surname>Zhang</surname><given-names>L. J.</given-names></name></person-group><article-title>Experimental study on the analgesia mechanism of Paeornia and Glycyrrhiza decoction</article-title><source><italic>Chinese Journal of Experimental Traditional Medical Formulae</italic></source><year>2002</year><volume>25</volume><issue>1</issue><fpage>23</fpage><lpage>25</lpage></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>H. N.</given-names></name><name><surname>Wang</surname><given-names>C. Y.</given-names></name><name><surname>Feng</surname><given-names>X. J.</given-names></name><name><surname>Liu</surname><given-names>R. M.</given-names></name><name><surname>Zhang</surname><given-names>J. Z.</given-names></name></person-group><article-title>Controlled study of shaoyao-gancao decoction and bromicripton in hyperprolactinemia</article-title><source><italic>J Clin Psychol Med</italic></source><year>2005</year><volume>15</volume><issue>6</issue><fpage>337</fpage><lpage>338</lpage></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fitzgerald</surname><given-names>P.</given-names></name><name><surname>Dinan</surname><given-names>T. G.</given-names></name></person-group><article-title>Prolactin and dopamine: what is the connection?</article-title><source><italic>Journal of Psychopharmacology</italic></source><year>2008</year><volume>22</volume><issue>supplement 2</issue><fpage>12</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1177/0269216307087148</pub-id><pub-id pub-id-type="other">2-s2.0-51149108773</pub-id><pub-id pub-id-type="pmid">18477617</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haddad</surname><given-names>P. M.</given-names></name><name><surname>Wieck</surname><given-names>A.</given-names></name></person-group><article-title>Antipsychotic-induced hyperprolactinaemia: Mechanisms, clinical features and management</article-title><source><italic>Drugs</italic></source><year>2004</year><volume>64</volume><issue>20</issue><fpage>2291</fpage><lpage>2314</lpage><pub-id pub-id-type="other">2-s2.0-6344253360</pub-id><pub-id pub-id-type="doi">10.2165/00003495-200464200-00003</pub-id><pub-id pub-id-type="pmid">15456328</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>B.-H.</given-names></name><name><surname>Kang</surname><given-names>S.-G.</given-names></name><name><surname>Kim</surname><given-names>T.-W.</given-names></name><name><surname>Lee</surname><given-names>H.-J.</given-names></name><name><surname>Yoon</surname><given-names>H.-K.</given-names></name><name><surname>Park</surname><given-names>Y.-M.</given-names></name></person-group><article-title>Hyperprolactinemia induced by low-dosage amisulpride in Korean psychiatric patients</article-title><source><italic>Psychiatry and Clinical Neurosciences</italic></source><year>2012</year><volume>66</volume><issue>1</issue><fpage>69</fpage><lpage>73</lpage><pub-id pub-id-type="other">2-s2.0-84862950065</pub-id><pub-id pub-id-type="doi">10.1111/j.1440-1819.2011.02296.x</pub-id><pub-id pub-id-type="pmid">22250612</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrade</surname><given-names>C.</given-names></name></person-group><article-title>Low-dose amisulpride and elevation in serum prolactin</article-title><source><italic>Journal of Clinical Psychiatry</italic></source><year>2013</year><volume>74</volume><issue>6</issue><fpage>e558</fpage><lpage>e560</lpage><pub-id pub-id-type="other">2-s2.0-84879580905</pub-id><pub-id pub-id-type="doi">10.4088/JCP.13f08510</pub-id><pub-id pub-id-type="pmid">23842026</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J. W.</given-names></name><name><surname>Park</surname><given-names>Y. M.</given-names></name><name><surname>Lee</surname><given-names>S. H.</given-names></name><name><surname>Kang</surname><given-names>S. G.</given-names></name><name><surname>Lee</surname><given-names>B. H.</given-names></name><name><surname>Park</surname><given-names>E.</given-names></name></person-group><article-title>Amisulpride-induced hyperprolactinemia:preliminary study</article-title><source><italic>Korean Journal of Psychosom Medicine</italic></source><year>2011</year><volume>19</volume><issue>1</issue><fpage>41</fpage><lpage>47</lpage></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>The contents of three major constituents contained in PGD preparation used in this study. A, paeoniflorin; B, liquiritin; C, glycyrrhetinic acid.</p></caption><graphic xlink:href="ECAM2017-7901670.001"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Mean levels of PRL in the study groups. Vertical bars represent standard deviations. Compared with placebo group, <sup><italic>&#x02217;&#x02217;</italic></sup><italic>p</italic> &#x0003c; 0.01.</p></caption><graphic xlink:href="ECAM2017-7901670.002"/></fig><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Mean levels of Estradiol in the study groups. Vertical bars represent standard deviations. Compared with placebo group, <sup><italic>&#x02217;</italic></sup><italic>p</italic> &#x0003c; 0.05.</p></caption><graphic xlink:href="ECAM2017-7901670.003"/></fig><fig id="fig4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Mean levels of Progesterone in the study groups. Vertical bars represent standard deviations. Compared with placebo group, <sup><italic>&#x02217;&#x02217;</italic></sup><italic>p</italic> &#x0003c; 0.01.</p></caption><graphic xlink:href="ECAM2017-7901670.004"/></fig><fig id="fig5" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Mean levels of FSH in the study groups. Vertical bars represent standard deviations.</p></caption><graphic xlink:href="ECAM2017-7901670.005"/></fig><fig id="fig6" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Mean levels of LH in the study groups. Vertical bars represent standard deviations.</p></caption><graphic xlink:href="ECAM2017-7901670.006"/></fig><fig id="fig7" orientation="portrait" position="float"><label>Figure 7</label><caption><p>Mean PANSS in the study groups. Vertical bars represent standard deviations.</p></caption><graphic xlink:href="ECAM2017-7901670.007"/></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline characteristics of participant.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="center" rowspan="1" colspan="1">Placebo (<italic>n</italic> = 20)</th><th align="center" rowspan="1" colspan="1">PGD (<italic>n</italic> = 21)</th><th align="center" rowspan="1" colspan="1">
<italic>p</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">28.55 &#x000b1; 5.24 (25.28&#x02013;31.12)</td><td align="center" rowspan="1" colspan="1">28.42 &#x000b1; 3.95 (26.95&#x02013;29.36)</td><td align="center" rowspan="1" colspan="1">0.93</td></tr><tr><td align="left" rowspan="1" colspan="1">Duration of the illness (months)</td><td align="center" rowspan="1" colspan="1">16.75 &#x000b1; 8.30 (11.72&#x02013;20.41)</td><td align="center" rowspan="1" colspan="1">17.14 &#x000b1; 7.15 (15.57&#x02013;20.11)</td><td align="center" rowspan="1" colspan="1">0.87</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of psychotic relapses</td><td align="center" rowspan="1" colspan="1">8 (40%)</td><td align="center" rowspan="1" colspan="1">9 (42.9%)</td><td align="center" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">Amisulpride treatment duration (months)</td><td align="center" rowspan="1" colspan="1">6.6 &#x000b1; 3.28 (4.50&#x02013;6.96)</td><td align="center" rowspan="1" colspan="1">7.09 &#x000b1; 2.36 (6.54&#x02013;8.08)</td><td align="center" rowspan="1" colspan="1">0.58</td></tr><tr><td align="left" rowspan="1" colspan="1">Amisulpride dosage</td><td align="center" rowspan="1" colspan="1">0.88 &#x000b1; 0.24 (0.78&#x02013;1.04)</td><td align="center" rowspan="1" colspan="1">0.85 &#x000b1; 0.26 (0.76&#x02013;0.92)</td><td align="center" rowspan="1" colspan="1">0.78</td></tr><tr><td align="left" rowspan="1" colspan="1">Hyperprolactinemia-related symptoms</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">0.98</td></tr><tr><td align="left" rowspan="1" colspan="1">Amenorrhea</td><td align="center" rowspan="1" colspan="1">5 (25%)</td><td align="center" rowspan="1" colspan="1">5 (23.8%)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">Abnormal menstruation</td><td align="center" rowspan="1" colspan="1">5 (25%)</td><td align="center" rowspan="1" colspan="1">4 (19%)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">Galactorrhea</td><td align="center" rowspan="1" colspan="1">4 (20%)</td><td align="center" rowspan="1" colspan="1">5 (23.8%)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">Reduced libido</td><td align="center" rowspan="1" colspan="1">4 (20%)</td><td align="center" rowspan="1" colspan="1">4 (19%)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">Sexlessness</td><td align="center" rowspan="1" colspan="1">2 (10%)</td><td align="center" rowspan="1" colspan="1">3 (14.3%)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">PRL (ng/mL)</td><td align="center" rowspan="1" colspan="1">46.25 &#x000b1; 5.43 (43.08&#x02013;48.78)</td><td align="center" rowspan="1" colspan="1">47.62 &#x000b1; 5.16 (45.63&#x02013;48.90)</td><td align="center" rowspan="1" colspan="1">0.41</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Hormone assays</italic>
</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">Estradiol (pg/mL)</td><td align="center" rowspan="1" colspan="1">54.25 &#x000b1; 27.98 (37.53&#x02013;73.14)</td><td align="center" rowspan="1" colspan="1">59.67 &#x000b1; 26.21 (49.55&#x02013;66.87)</td><td align="center" rowspan="1" colspan="1">0.53</td></tr><tr><td align="left" rowspan="1" colspan="1">Progesterone (ng/mL)</td><td align="center" rowspan="1" colspan="1">16.10 &#x000b1; 4.01 (13.77&#x02013;17.43)</td><td align="center" rowspan="1" colspan="1">16.57 &#x000b1; 3.59 (15.41&#x02013;17.54)</td><td align="center" rowspan="1" colspan="1">0.69</td></tr><tr><td align="left" rowspan="1" colspan="1">FSH (IU/L)</td><td align="center" rowspan="1" colspan="1">14.75 &#x000b1; 3.80 (13.60&#x02013;17.74)</td><td align="center" rowspan="1" colspan="1">13.52 &#x000b1; 2.82 (12.53&#x02013;14.41)</td><td align="center" rowspan="1" colspan="1">0.25</td></tr><tr><td align="left" rowspan="1" colspan="1">LH (IU/L)</td><td align="center" rowspan="1" colspan="1">27.15 &#x000b1; 10.62 (22.45&#x02013;28.03)</td><td align="center" rowspan="1" colspan="1">23.43 &#x000b1; 6.48 (20.72&#x02013;24.96)</td><td align="center" rowspan="1" colspan="1">0.19</td></tr><tr><td align="left" rowspan="1" colspan="1">Initial PANSS score</td><td align="center" rowspan="1" colspan="1">50.45 &#x000b1; 4.04 (48.45&#x02013;52.88)</td><td align="center" rowspan="1" colspan="1">52.76 &#x000b1; 4.65 (51.12&#x02013;54.24)</td><td align="center" rowspan="1" colspan="1">0.08</td></tr><tr><td align="left" rowspan="1" colspan="1">Positive subscale</td><td align="center" rowspan="1" colspan="1">19.85 &#x000b1; 3.95 (18.22&#x02013;21.38)</td><td align="center" rowspan="1" colspan="1">20.52 &#x000b1; 3.31 (19.12&#x02013;21.20)</td><td align="center" rowspan="1" colspan="1">0.60</td></tr><tr><td align="left" rowspan="1" colspan="1">Negative subscale</td><td align="center" rowspan="1" colspan="1">12.00 &#x000b1; 3.34 (10.87&#x02013;14.06)</td><td align="center" rowspan="1" colspan="1">13.71 &#x000b1; 3.68 (12.55&#x02013;15.03)</td><td align="center" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" rowspan="1" colspan="1">General subscale</td><td align="center" rowspan="1" colspan="1">18.60 &#x000b1; 2.64 (16.95&#x02013;19.84)</td><td align="center" rowspan="1" colspan="1">18.52 &#x000b1; 4.48 (17.23&#x02013;20.24)</td><td align="center" rowspan="1" colspan="1">0.95</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Biochemical indexes</italic>
</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">ALT (U/L)</td><td align="center" rowspan="1" colspan="1">33.85 &#x000b1; 12.93 (27.03&#x02013;42.17)</td><td align="center" rowspan="1" colspan="1">36.33 &#x000b1; 10.46 (32.06&#x02013;38.99)</td><td align="center" rowspan="1" colspan="1">0.50</td></tr><tr><td align="left" rowspan="1" colspan="1">AST (U/L)</td><td align="center" rowspan="1" colspan="1">29.55 &#x000b1; 10.67 (25.44&#x02013;37.49)</td><td align="center" rowspan="1" colspan="1">33.52 &#x000b1; 7.68 (30.39&#x02013;34.87)</td><td align="center" rowspan="1" colspan="1">0.18</td></tr><tr><td align="left" rowspan="1" colspan="1">BUN (mmol/L)</td><td align="center" rowspan="1" colspan="1">5.47 &#x000b1; 2.26 (4.61&#x02013;7.15)</td><td align="center" rowspan="1" colspan="1">5.34 &#x000b1; 1.51 (4.78&#x02013;5.78)</td><td align="center" rowspan="1" colspan="1">0.83</td></tr><tr><td align="left" rowspan="1" colspan="1">CRE (<italic>&#x003bc;</italic>mol/L)</td><td align="center" rowspan="1" colspan="1">69.24 &#x000b1; 15.09 (60.98&#x02013;79.78)</td><td align="center" rowspan="1" colspan="1">68.77 &#x000b1; 10.66 (64.18&#x02013;70.83)</td><td align="center" rowspan="1" colspan="1">0.91</td></tr><tr><td align="left" rowspan="1" colspan="1">TG (mmol/L)</td><td align="center" rowspan="1" colspan="1">2.92 &#x000b1; 1.70 (2.04&#x02013;3.96)</td><td align="center" rowspan="1" colspan="1">2.89 &#x000b1; 1.51 (2.24&#x02013;3.17)</td><td align="center" rowspan="1" colspan="1">0.95</td></tr><tr><td align="left" rowspan="1" colspan="1">GLU (mmol/L)</td><td align="center" rowspan="1" colspan="1">4.76 &#x000b1; 0.76 (4.26&#x02013;5.00)</td><td align="center" rowspan="1" colspan="1">4.98 &#x000b1; 0.68 (4.74&#x02013;5.19)</td><td align="center" rowspan="1" colspan="1">0.32</td></tr><tr><td align="left" rowspan="1" colspan="1">TSH (uIU/mL)</td><td align="center" rowspan="1" colspan="1">6.45 &#x000b1; 2.36 (5.14&#x02013;8.07)</td><td align="center" rowspan="1" colspan="1">7.73 &#x000b1; 1.75 (7.08&#x02013;8.27)</td><td align="center" rowspan="1" colspan="1">0.054</td></tr></tbody></table><table-wrap-foot><fn><p>Data given as <italic>n</italic> (%) or mean &#x000b1; standard deviation (95% CI (confidential intervals)); PRL = Prolactin; FSH = Follicle-stimulating hormone; LH = Luteinizing hormone; PANSS = Positive and Negative Syndrome Scale; ALT = alanine aminotransferase; AST = aspartate transaminase; BUN = blood urea nitrogen; CRE = creatinine; TG = triglyceride; GLU = blood glucose; TSH = thyroid stimulating hormone; NS = nonsignificant.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Biochemical indexes after 8 weeks.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="center" rowspan="1" colspan="1">Placebo (<italic>n</italic> = 15)</th><th align="center" rowspan="1" colspan="1">PGD (<italic>n</italic> = 19)</th><th align="center" rowspan="1" colspan="1">
<italic>p</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">ALT (U/L)</td><td align="center" rowspan="1" colspan="1">38.00 &#x000b1; 9.70 (32.63&#x02013;43.37)</td><td align="center" rowspan="1" colspan="1">36.32 &#x000b1; 10.04 (33.06&#x02013;39.57)</td><td align="center" rowspan="1" colspan="1">0.62</td></tr><tr><td align="left" rowspan="1" colspan="1">AST (U/L)</td><td align="center" rowspan="1" colspan="1">32.27 &#x000b1; 9.64 (26.93&#x02013;37.61)</td><td align="center" rowspan="1" colspan="1">35.32 &#x000b1; 7.97 (32.73&#x02013;37.90)</td><td align="center" rowspan="1" colspan="1">0.32</td></tr><tr><td align="left" rowspan="1" colspan="1">BUN (mmol/L)</td><td align="center" rowspan="1" colspan="1">5.93 &#x000b1; 2.13 (4.75&#x02013;7.11)</td><td align="center" rowspan="1" colspan="1">5.59 &#x000b1; 1.09 (5.24&#x02013;5.94)</td><td align="center" rowspan="1" colspan="1">0.58</td></tr><tr><td align="left" rowspan="1" colspan="1">CRE (<italic>&#x003bc;</italic>mol/L)</td><td align="center" rowspan="1" colspan="1">71.47 &#x000b1; 14.91 (63.21&#x02013;79.72)</td><td align="center" rowspan="1" colspan="1">65.91 &#x000b1; 9.54 (62.82&#x02013;69.00)</td><td align="center" rowspan="1" colspan="1">0.20</td></tr><tr><td align="left" rowspan="1" colspan="1">TG (mmol/L)</td><td align="center" rowspan="1" colspan="1">3.20 &#x000b1; 1.46 (2.39&#x02013;4.01)</td><td align="center" rowspan="1" colspan="1">2.85 &#x000b1; 1.15 (2.48&#x02013;3.23)</td><td align="center" rowspan="1" colspan="1">0.44</td></tr><tr><td align="left" rowspan="1" colspan="1">GLU (mmol/L)</td><td align="center" rowspan="1" colspan="1">4.72 &#x000b1; 0.67 (4.35&#x02013;5.10)</td><td align="center" rowspan="1" colspan="1">5.08 &#x000b1; 0.58 (4.89&#x02013;5.27)</td><td align="center" rowspan="1" colspan="1">0.32</td></tr><tr><td align="left" rowspan="1" colspan="1">TSH (uIU/mL)</td><td align="center" rowspan="1" colspan="1">6.41 &#x000b1; 2.27 (5.15&#x02013;7.66)</td><td align="center" rowspan="1" colspan="1">7.31 &#x000b1; 1.81 (7.08&#x02013;8.27)</td><td align="center" rowspan="1" colspan="1">0.21</td></tr></tbody></table><table-wrap-foot><fn><p>Data given as <italic>n</italic> (%) or mean &#x000b1; standard deviation (95% CI (confidential intervals)).</p></fn></table-wrap-foot></table-wrap></floats-group></article>